November 2016 | Vol 40 issue No 3

Breast cancer: a disease of subtypes

Guest Editor: Nicholas Wilcken

Download entire issue

Forum

Breast cancer: a disease of subtypes

Nicholas Wilcken

Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections

Clara I Lee and Howard Gurney

Bone health in the treatment of postmenopausal women with aromatase inhibitors and premenopausal women treated with ovarian suppression and aromatase inhibitors: a hands-on guide

Clara I Lee

The ‘enablers’: inhibitors of mTOR, PI3K and CDK that prolong endocrine sensitivity

Nicholas Wilcken

Triple negative breast cancer: proven and promising systemic therapies

Alice Bergin, Catherine Oakman, Geoffrey J Lindeman

Adjuvant therapy for HER2 positive disease: can we do better, or are we already giving too much treatment?

Nicholas Wilcken

HER2 positive metastatic breast cancer: what happens after first line failure?

Arlene Chan

Brain metastases: a subtype-specific medical approach

Claire Phillips

Immunotherapy in breast cancer: the subtype story

Stephen J Luen and Sherene Loi

Obituaries

Professor Umberto Veronesi MD OMRI

W Brian Fleming

Articles

Clinical Oncology Society of Australia Cancer Care Coordinator Position Statement Summary

Awards

Cancer Council Australia Student Essay Competition 2016: How best to teach and learn about cancer in medical schools: moving towards a patient-centred approach that reflects the needs of Australia

Robert J McRae

Reports

Behavioural Research and Evaluation (BREU), South Australia

Centre for Behavioural Research in Cancer (CBRC), Victoria

Newcastle Cancer Control Collaborative (New-3C), NSW

Western Australian Cancer Prevention Research Unit (WACPRU), Curtin University

Cancer Council Australia

Clinical Oncology Society of Australia, COSA

Ms Marie Malica

Faculty of Radiation Oncology, RANZCR

Dr Dion Forstner

Medical Oncology Group of Australia, MOGA

Ms Kay Francis